Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02155
European Journal of Endocrinology, Vol 154, Issue 6, 819-825
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brouwer, J. P
Right arrow Articles by Fliers, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brouwer, J. P
Right arrow Articles by Fliers, E.
CLINICAL STUDY

Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression

Jantien P Brouwer1, Bente C Appelhof1, Robin P Peeters4, Witte J G Hoogendijk5, Jochanan Huyser2, Aart H Schene2, Jan G P Tijssen3, Richard Van Dyck5, Theo J Visser4, Wilmar M Wiersinga1 and Eric Fliers1

1 Departments of Endocrinology, 2 Psychiatry and 3 Cardiology, Academic Medical Center, Meibergdreef 9, 1101, Amsterdam, The Netherlands, 4 Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands and 5 Department of Psychiatry, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.

(Correspondence should be addressed to J P Brouwer; Email: j.p.brouwer{at}amc.uva.nl)

Objective: The determinants of response to antidepressant treatment in major depression are unknown at present. The aim of the present study was to establish whether response is predicted by Hypothalamus–Pituitary–Thyroid (HPT) axis parameters or by a recently discovered polymorphism in the enzyme type II deiodinase (DII), which catalyzes the production of T3 in the brain.

Design: We analyzed prediction of response to paroxetine treatment by calculating response rates per tertile of HPT-axis parameters and per DII genotype.

Methods: Ninety-eight outpatients with major depression (DSM-IV) were included. Serum concentrations of TSH, FT4 and delta TSH in a DEX/CRH-TRH test were measured. In addition, the presence of a polymorphism in the DII sequence (Thr92Ala) was determined.

Results: The overall treatment response was 48 of 98 patients (49%). After exclusion of patients with subclinical hypothyroidism and/or TPO antibodies (n = 16), higher serum TSH significantly predicted response (response rate per tertile from low to high TSH: 36%, 42%, and 67%). Heterozygous patients for the DII polymorphism (44%) had slightly lower serum TSH (P = 0.03) as compared to patients with the wild-type DII (47%). The polymorphism was unrelated to treatment response.

Conclusion: Higher serum TSH was associated with response to paroxetine in patients with major depression.




This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
R. Cooper-Kazaz, J. T. Apter, R. Cohen, L. Karagichev, S. Muhammed-Moussa, D. Grupper, T. Drori, M. E. Newman, H. A. Sackeim, B. Glaser, et al.
Combined Treatment With Sertraline and Liothyronine in Major Depression: A Randomized, Double-blind, Placebo-Controlled Trial
Arch Gen Psychiatry, June 1, 2007; 64(6): 679 - 688.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.